Eddie Hickman
Stock Analyst at Guggenheim
(4.53)
# 258
Out of 5,124 analysts
20
Total ratings
68.42%
Success rate
24.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYBN Cybin | Maintains: Buy | $39 → $48 | $8.18 | +486.80% | 2 | Dec 3, 2025 | |
| PMN ProMIS Neurosciences | Maintains: Buy | $150 → $125 | $6.83 | +1,731.50% | 3 | Nov 18, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $84 → $87 | $81.88 | +6.25% | 9 | Nov 5, 2025 | |
| OTLK Outlook Therapeutics | Downgrades: Neutral | n/a | $1.58 | - | 4 | Aug 29, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $20 → $22 | $8.96 | +145.54% | 1 | Mar 13, 2025 | |
| GHRS GH Research | Initiates: Buy | $32 | $12.70 | +151.97% | 1 | Mar 13, 2025 |
Cybin
Dec 3, 2025
Maintains: Buy
Price Target: $39 → $48
Current: $8.18
Upside: +486.80%
ProMIS Neurosciences
Nov 18, 2025
Maintains: Buy
Price Target: $150 → $125
Current: $6.83
Upside: +1,731.50%
Tarsus Pharmaceuticals
Nov 5, 2025
Maintains: Buy
Price Target: $84 → $87
Current: $81.88
Upside: +6.25%
Outlook Therapeutics
Aug 29, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.58
Upside: -
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $8.96
Upside: +145.54%
GH Research
Mar 13, 2025
Initiates: Buy
Price Target: $32
Current: $12.70
Upside: +151.97%